Florian Reinaud
Venture Partner
Works at Redmile Group
Investor profile | Builders Republic
About
Venture Partner at Redmile Group in Paris, Florian Reinaud invests in Series A to pre-IPO in life sciences companies, with a strong expertise in biotech, medtech, and digital health. His portfolio notably focuses on orthopedic assets and late-stage biotech: he sits on the board of Zealand Pharma (Nasdaq), Kuros Biosurgery (SIX), and Voluntis, which was exited to AstraZeneca. Former founding CEO of Concilio, a healthtech platform he led until 2022, he was also CFO of DBV Technologies and Principal at Apax Partners. A physician graduated from Imperial College London, he is also an alumnus of Oxford.
Profile
- Role
- Venture Partner
- Fund
- Redmile Group
- Nationality
- French